Remus Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical sector, has taken a significant regulatory step by submitting a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending March 31, 2025. The certificate, issued by MUFG Intime India Private Limited (formerly known as Link Intime India Pvt. Ltd.), verifies that the company has strictly complied with the dematerialisation requirements as mandated by the regulatory authorities.

Background of SEBI Regulation 74(5)

Regulation 74(5) is part of the SEBI (Depositories and Participants) Regulations, 2018, which governs the dematerialisation and rematerialisation of securities in India. Under this regulation, companies must confirm that:

• Securities submitted by depository participants for dematerialisation are processed properly.

• Certificates are mutilated and cancelled after verification.

• Depositories are reflected correctly as registered owners in the company’s books.

• All actions are completed within prescribed timelines to maintain transparency and investor confidence.

Remus Pharmaceuticals’ Compliance Update

In a filing dated April 14, 2025, Remus Pharmaceuticals Limited informed the National Stock Exchange (NSE) that it has received the Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited. The certificate pertains to the quarter ended March 31, 2025 and confirms that all required processes were followed accurately.

Deval Patel, the Company Secretary and Compliance Officer of Remus Pharmaceuticals, signed the submission, affirming that the company is fully aligned with SEBI’s standards for dematerialisation.

Confirmation by MUFG Intime India

The RTA, MUFG Intime India Private Limited, plays a critical role in handling shareholder services, including dematerialisation, rematerialisation, and transfer of shares. In its official communication dated April 2, 2025, addressed to Remus Pharmaceuticals, MUFG confirmed the following:

• All securities received from depository participants for dematerialisation during the January–March 2025 quarter were duly confirmed and processed.

• The details of securities matched existing records, ensuring accurate listing on stock exchanges.

• All physical security certificates were mutilated and cancelled post-verification.

• The name of the relevant depository (NSDL or CDSL) has been substituted in the company’s register of members within the required timeframe.

The certificate was signed by Ashok Shetty, Vice President – Corporate Registry at MUFG Intime, further lending credibility to the process.

Importance of the Compliance Certificate

This regulatory filing is crucial for several reasons:

• Investor Confidence: By demonstrating strict adherence to SEBI norms, Remus Pharmaceuticals reinforces its commitment to transparency and corporate governance.

• Operational Transparency: It showcases the seamless functioning between the company, depositories, and registrar agents, reducing potential for fraud or errors in shareholding records.

• Regulatory Standing: Filing such confirmations regularly ensures that the company remains in good standing with stock exchanges and regulators.

About Remus Pharmaceuticals Limited

Remus Pharmaceuticals Limited is a reputed pharmaceutical company based in Ahmedabad, Gujarat. The company is known for its commitment to quality, regulatory compliance, and innovation in healthcare products. As of this writing, the company’s shares are traded on the National Stock Exchange (NSE) under the symbol REMUS.

Their registered office is located at: 1101 TO 1103, South Tower, ONE 42, B/H Ashok Vatika, Near Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad - 380054

About MUFG Intime India Private Limited

MUFG Intime India Pvt. Ltd., formerly Link Intime India Pvt. Ltd., is one of the leading Registrar and Share Transfer Agents in India. They provide services to many top companies listed on BSE, NSE, and SME platforms. The company is part of MUFG Corporate Markets, a division of MUFG Pension & Market Services, and offers integrated corporate market solutions.

They are headquartered at: C-101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400083

Their core services include:

• Investor record management

• Shareholder communication

• IPO and FPO handling

• Regulatory reporting and compliance services

What This Means for Shareholders

For existing and potential investors of Remus Pharmaceuticals, this compliance certificate sends a positive signal about the company’s governance and operational integrity. It confirms that:

• Their dematerialised shares are secure and accurately recorded.

• There are no pending issues regarding physical securities.

• The company maintains a high standard of compliance with SEBI norms.

Such practices ensure long-term shareholder value protection and create trust in the corporate ecosystem.

Final Thoughts

Regulatory compliance in India’s capital market is not just a formality but a foundational aspect of transparent and sustainable business operations. Companies like Remus Pharmaceuticals Limited set an example by promptly filing their confirmation certificates and maintaining strong coordination with their RTA and depositories.

As the company grows and scales its operations in the pharmaceutical domain, such filings ensure its reputation remains intact, and it continues to be seen as a responsible, investor-friendly organisation.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.